MariMed Inc. reports news on its multi-state cannabis operating platform, including cultivation, production, branded consumer products and retail dispensaries. Company updates commonly cover financial results, earnings-call schedules, wholesale distribution, branded product activity and retail operations tied to names such as Betty's Eddies, Bubby’s Baked, InHouse, Nature’s Heritage, Vibations and Thrive Dispensary.
Recurring developments also include capital-structure actions, preferred-stock obligations, hemp-derived THC product launches, cannabis regulatory commentary and community initiatives associated with the company's dispensary and brand portfolio.
MariMed Inc. (CSE: MRMD, OTCQX: MRMD) has appointed Kathleen Tucker to its Board of Directors, enhancing its leadership in the cannabis sector. Tucker brings over 25 years of experience in consumer marketing, product development, and operations. She has previously served as CEO of Presence Enterprises and COO of MariMed's subsidiary and 3C Compassionate Care Center. Tucker holds an MBA and B.S. in Operations and Computer Science from Northern Illinois University. MariMed aims to strengthen its brand appeal and customer experience with Tucker's insights, as stated by CEO Jon Levine. The company continues to focus on high-quality, innovative cannabis products across its multiple operations.
MariMed Inc. (CSE: MRMD, OTCQX: MRMD), a leading multi-state cannabis operator, will report its Q1 2023 financial results on May 8, 2023, after market close. Management will host a conference call on May 9, 2023, at 8:00 a.m. EST to discuss the financial outcomes. The call will be accessible via a webcast on MariMed’s Investor Relations website, where a playback will also be available. MariMed is dedicated to improving lives through its high-quality cannabis products, utilizing state-licensed facilities and proprietary formulations that underpin its popular brands such as Betty's Eddies and Nature’s Heritage.
MariMed (CSE: MRMD) announced that its subsidiary, Kind Therapeutics USA, has received approval from the Maryland Medical Cannabis Commission to produce and distribute higher-dosage THC-infused edibles. Following the acquisition of Good Manufacturing Practice (GMP) certification for its Hagerstown facility, MariMed can now offer 40mg products, starting with the popular Betty’s Eddies fruit chews. This move comes as Maryland prepares for adult-use cannabis sales, expected to begin in July 2023. The company operates a 90,000 square foot production facility and has a strong presence across over 100 dispensaries statewide, positioning itself for significant growth.
MariMed Inc. (CSE: MRMD, OTCQX: MRMD), a prominent multi-state cannabis operator, recently announced its participation in key investor conferences. CEO Jon Levine will speak at the Benzinga Cannabis Capital Conference on April 11 in Miami, engaging in a panel on growth insights for 2023 and a fireside chat on April 12. CFO Susan Villare will conduct one-on-one meetings at Canaccord Genuity's 7th Annual Global Cannabis Conference in New York on May 18. MariMed focuses on excellence in cannabis cultivation and infused products, offering top-selling brands like Betty's Eddies and Nature’s Heritage.
MariMed, Inc. (CSE: MRMD) has successfully completed the acquisition of Ermont Inc.'s operating assets, enhancing its presence in Massachusetts as the second medical dispensary opens under the Panacea Wellness brand. This acquisition, finalized on March 9, 2023, follows the Company’s goal of maximizing its footprint within state regulations. The deal includes two Host Community Agreements, one for adult-use cannabis sales, and plans to expand operations to meet growing demand. The transaction, the first cannabis receivership in New England, was approved by the Massachusetts Cannabis Control Commission, offering a strategic advantage in the evolving cannabis market.
MariMed reported its financial results for Q4 and full-year 2022, highlighting a revenue increase to $35.8 million for the quarter, up from $31 million in Q4 2021. Full-year revenue reached $134 million, marking a growth from $121.5 million in 2021. The company achieved a GAAP net income of $4.8 million, a positive turnaround from a loss of $6.4 million in Q4 2021. Positive cash flows from operations were maintained for the third consecutive year. For 2023, MariMed anticipates revenues exceeding $150 million and plans to open four new dispensaries. The company aims to leverage its strong balance sheet and operational capabilities for accelerated growth.
MariMed, Inc. (CSE: MRMD, OTCQX: MRMD) announced a leadership change on February 28, 2023, appointing Jon Levine as Chief Executive Officer and Edward Gildea as Chairman of the Board. Levine, co-founder of MariMed, has been serving as Interim CEO since the passing of Bob Fireman in December. The Board believes Levine's extensive industry experience positions him well to continue the company's mission established by the founders. Gildea praised Levine's leadership and vision, indicating strong support from the Board for the strategic plan moving forward.
MariMed (CSE: MRMD) plans to acquire the operating assets of Ermont, a vertically integrated cannabis operator in Quincy, MA, currently in receivership. The acquisition, pending approval from the Massachusetts Cannabis Control Commission, would mark MariMed's third dispensary in the state, furthering its strategic objective to expand its footprint. Funded through a credit facility with Chicago Atlantic, this acquisition is expected to significantly enhance MariMed's operations by allowing the rebranding of the dispensary to Panacea Wellness and broadening its product offerings. The Massachusetts cannabis market generated $1.8 billion in sales in 2022.
MariMed Inc. (CSE: MRMD, OTCQX: MRMD), a multi-state cannabis operator, announced it will release its Q4 2022 financial results on March 1, 2023, after market close. Following this, management will host a conference call on March 2, 2023, at 8:00 a.m. EST to discuss the results. Investors can access a webcast of the earnings call via MariMed's Investor Relations website. The company focuses on high-quality cannabis products and operates state-licensed facilities, aiming to enhance lives through its innovative offerings. For more information, visit www.marimedinc.com.
MariMed closed a $35 million secured credit facility with Chicago Atlantic Advisors on January 24, 2023, to enhance its growth and expansion initiatives. The company initially borrowed $30 million, with an option for an additional $5 million within six months. The funds will finance the build-out of cultivation facilities in Illinois and Missouri, expand existing operations in Massachusetts and Maryland, and repay seller notes from a previous acquisition. The facility features a floating interest rate and a Debt/EBITDA ratio of 1.5X, reflecting a solid balance sheet among cannabis operators.